Current and historical daily PE Ratio for Seagen Inc (
MEX:SGEN
) from 2020 to Jun 17 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Seagen stock (MEX:SGEN) PE ratio as of Jun 17 2024 is 0.
More Details
Seagen Inc (MEX:SGEN) PE Ratio (TTM) Chart
Seagen Inc (MEX:SGEN) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 410
- 1
- 2
- 3
- 4
- 5
| Seagen PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-17 | At Loss | 2024-02-02 | At Loss |
| 2024-04-05 | At Loss | 2024-02-01 | At Loss |
| 2024-04-04 | At Loss | 2024-01-31 | At Loss |
| 2024-04-03 | At Loss | 2024-01-30 | At Loss |
| 2024-04-02 | At Loss | 2024-01-29 | At Loss |
| 2024-04-01 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | At Loss |
| 2024-02-27 | At Loss | 2023-12-26 | At Loss |
| 2024-02-26 | At Loss | 2023-12-25 | At Loss |
| 2024-02-23 | At Loss | 2023-12-22 | At Loss |
| 2024-02-22 | At Loss | 2023-12-21 | At Loss |
| 2024-02-21 | At Loss | 2023-12-20 | At Loss |
| 2024-02-20 | At Loss | 2023-12-19 | At Loss |
| 2024-02-19 | At Loss | 2023-12-18 | At Loss |
| 2024-02-16 | At Loss | 2023-12-15 | At Loss |
| 2024-02-15 | At Loss | 2023-12-14 | At Loss |
| 2024-02-14 | At Loss | 2023-12-13 | At Loss |
| 2024-02-13 | At Loss | 2023-12-12 | At Loss |
| 2024-02-12 | At Loss | 2023-12-11 | At Loss |
| 2024-02-09 | At Loss | 2023-12-08 | At Loss |
| 2024-02-08 | At Loss | 2023-12-07 | At Loss |
| 2024-02-07 | At Loss | 2023-12-06 | At Loss |
| 2024-02-06 | At Loss | 2023-12-05 | At Loss |
| 2024-02-05 | At Loss | 2023-12-04 | At Loss |
Seagen Inc (MEX:SGEN) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Seagen Inc
NAICS : 325414
SIC : 2836
ISIN : US81181C1045
Share Class Description:
MEX:SGEN: Ordinary SharesCompare
Compare
Traded in other countries / regions
SGEN.Mexico IPO Date
2020-04-12Description
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers